KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Goodwill (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Goodwill for 17 consecutive years, with $196.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Goodwill changed 0.0% year-over-year to $196.2 million, compared with a TTM value of $196.2 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $196.2 million, changed 0.0% over the prior year.
  • Goodwill was $196.2 million for Q3 2025 at Biomarin Pharmaceutical, roughly flat from $196.2 million in the prior quarter.
  • Across five years, Goodwill topped out at $196.2 million in Q2 2021 and bottomed at $196.2 million in Q2 2021.
  • Average Goodwill over 5 years is $196.2 million, with a median of $196.2 million recorded in 2021.
  • Peak annual rise in Goodwill hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
  • Year by year, Goodwill stood at $196.2 million in 2021, then changed by 0.0% to $196.2 million in 2022, then changed by 0.0% to $196.2 million in 2023, then changed by 0.0% to $196.2 million in 2024, then changed by 0.0% to $196.2 million in 2025.
  • Business Quant data shows Goodwill for BMRN at $196.2 million in Q3 2025, $196.2 million in Q2 2025, and $196.2 million in Q1 2025.